Juvenile Polyposis Syndrome

Definition and Diagnostic Criteria

The American College of Gastroenterology recommends that a diagnosis of Juvenile Polyposis Syndrome (JPS) be considered when any of the following criteria are met: five or more juvenile polyps in the colorectum, juvenile polyps throughout the gastrointestinal tract, or any number of juvenile polyps with a positive family history of JPS, with a lifetime colorectal cancer risk of 39-68% and gastric cancer risk of 21% in those with gastric polyps 1, 2, 3
The syndrome occurs in approximately 1 per 100,000 newborns, making it about 10 times less common than familial adenomatous polyposis, according to the National Comprehensive Cancer Network 1, 4

The European Society of Gastrointestinal Endoscopy notes that juvenile polyps have distinctive microscopic characteristics, including hamartomatous architecture with dense, edematous stroma, and absence of the smooth muscle branching pattern seen in Peutz-Jeghers polyps 2, 5

The American Gastroenterological Association reports that typical symptoms of JPS include rectal bleeding and anemia, diarrhea, abdominal pain, and protein-losing enteropathy, with polyp numbers typically ranging from 50-200 in the colon 1, 2, 4, 5

The European Society for Medical Oncology recommends that the primary treatment consists of repeated endoscopic polypectomy at 2-year intervals for both colorectal and upper gastrointestinal polyps, aiming to reduce cancer risk and prevent symptoms 1, 4
Colectomy with ileorectal anastomosis is appropriate for patients with high polyp burden in the colon, according to the American Society of Colon and Rectal Surgeons 1, 4

The National Cancer Institute states that patients with JPS have a cumulative lifetime colorectal cancer risk of 39-68%, with a relative risk of 34 compared to the general population, and a 21% risk of gastric cancer in those with gastric polyps 1, 5
The American College of Medical Genetics and Genomics notes that SMAD4 mutations carry additional risk, including hereditary hemorrhagic telangiectasia-JPS complex, requiring cardiovascular surveillance for arteriovenous malformations 5